Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCABNASDAQ:CGTXNYSE:CVMNASDAQ:ONCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.49-1.9%$0.35$0.24▼$3.53$28.40M1.08982,282 shs518,229 shsCGTXCognition Therapeutics$0.43+2.3%$0.41$0.31▼$2.95$26.46M1.012.54 million shs240,231 shsCVMCEL-SCI$0.29$0.27$0.18▼$2.39$24.40M0.951.05 million shs582,884 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla+11.35%+43.18%+32.71%+6.97%-80.80%CGTXCognition Therapeutics+0.17%+10.63%+0.36%-45.16%-78.38%CVMCEL-SCI-4.57%+6.74%+21.49%-24.75%-79.36%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.92 of 5 stars3.33.00.00.02.62.51.3CGTXCognition Therapeutics3.5573 of 5 stars3.55.00.00.02.52.51.3CVMCEL-SCIN/AN/AN/AN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$6.001,134.06% UpsideCGTXCognition Therapeutics 3.00Buy$7.131,569.01% UpsideCVMCEL-SCI 0.00N/AN/AN/AONCESpark Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCE, BCAB, CGTX, and CVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025BCABBioAtlaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/24/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.003/21/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.002/26/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M2.58N/AN/A$1.47 per share0.33CGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AONCESpark Therapeutics$64.72M0.11N/AN/A$13.15 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$123.46M-$1.44N/AN/AN/AN/A-187.30%-96.33%5/6/2025 (Estimated)CGTXCognition Therapeutics-$25.79M-$0.87N/AN/AN/AN/A-150.93%-100.82%5/6/2025 (Estimated)CVMCEL-SCI-$26.92M-$0.48N/AN/AN/AN/A-238.05%-104.65%N/AONCESpark Therapeutics-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/ALatest ONCE, BCAB, CGTX, and CVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025BCABBioAtla-$0.28N/AN/AN/AN/AN/A5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12N/AN/AN/AN/AN/A3/27/2025Q4 2024BCABBioAtla-$0.40-$0.32+$0.08-$0.34N/AN/A3/20/2025Q4 2024CGTXCognition Therapeutics-$0.16-$0.17-$0.01-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A3.113.11CGTXCognition TherapeuticsN/A2.112.11CVMCEL-SCI0.661.071.09ONCESpark Therapeutics0.354.674.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CGTXCognition Therapeutics43.35%CVMCEL-SCI12.08%ONCESpark Therapeutics88.37%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%CGTXCognition Therapeutics20.75%CVMCEL-SCI14.06%ONCESpark Therapeutics6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.40 million42.79 millionOptionableCGTXCognition Therapeutics2061.97 million32.93 millionNot OptionableCVMCEL-SCI4384.12 million64.67 millionOptionableONCESpark Therapeutics36838.52 millionN/ANo DataONCE, BCAB, CGTX, and CVM HeadlinesRecent News About These CompaniesHow Spark's layoffs could affect University City real estateApril 11, 2025 | bizjournals.comDespite Spark's massive layoffs, co-founder Jeff Marrazzo says its legacy will endureApril 9, 2025 | bizjournals.comSpark Therapeutics files notice to lay off 300 employees this yearApril 5, 2025 | technical.lySpark Therapeutics Cuts 298 Employees as Part of ReorganizationApril 4, 2025 | biospace.comSpark Therapeutics is laying off 337 people, more than half its workforce, starting in MayApril 4, 2025 | msn.comDoes the Spark Therapeutics writedown undermine Philly’s biotech swagger?March 18, 2025 | technical.lyRoche to buy gene therapy firm Spark for $4.8 billionMarch 13, 2025 | pharmaphorum.comRoche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy UnitMarch 12, 2025 | biospace.comSpark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downsMarch 4, 2025 | msn.comPfizer shelves Beqvez, a Spark Therapeutics developed productFebruary 24, 2025 | bizjournals.comSpark Therapeutics co-founder back at the helm of a Philadelphia gene therapy companyJanuary 14, 2025 | bizjournals.comSpark reassures on safety of haemophilia gene therapyDecember 25, 2024 | pharmaphorum.comRoche mothballs another hemophilia A gene therapy under Spark amid plans to debut new hematologic assetDecember 17, 2024 | fiercebiotech.comHow ADHD wired me for scientific discoveryNovember 12, 2024 | statnews.comHuntington Study Group (HSG) Conference 2024 – Day 1November 11, 2024 | en.hdbuzz.netBitcoin breaks $81,000 for first time on Trump trades; UK government sells £1bn of NatWest shares – business liveNovember 11, 2024 | msn.comMeet the contenders: Vote for the winners of Philly’s 2024 Technical.ly AwardsNovember 7, 2024 | technical.lyDenver police investigate deadly hit-and-run at South Sheridan and Evans AvenueNovember 6, 2024 | yahoo.comTrump trades: US dollar, stock futures, bonds, BitcoinNovember 6, 2024 | sharecafe.com.auAmazon Prime vs. Walmart+: Which Offers the Better Discount on Gas?November 5, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesInvestors Sell Microsoft Stock on OpenAI News—Time to Buy? By Chris Markoch | April 22, 2025View Investors Sell Microsoft Stock on OpenAI News—Time to Buy? Viking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold Gains3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside Marvell Gets Tariff Lifeline But Expect More VolatilityBy Chris Markoch | April 11, 2025View Marvell Gets Tariff Lifeline But Expect More Volatility 2 Reasons to Buy Apple Stock and 1 Significant RiskBy Chris Markoch | April 2, 2025View 2 Reasons to Buy Apple Stock and 1 Significant RiskONCE, BCAB, CGTX, and CVM Company DescriptionsBioAtla NASDAQ:BCAB$0.49 -0.01 (-1.86%) As of 04:00 PM EasternBioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Cognition Therapeutics NASDAQ:CGTX$0.43 +0.01 (+2.33%) As of 04:00 PM EasternCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.CEL-SCI NYSE:CVM$0.29 0.00 (0.00%) As of 04:00 PM EasternCEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Spark Therapeutics NASDAQ:ONCESpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
